HIGHLIGHTS
- who: Caitlin Molczyk and Rakesh K. Singh from the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA have published the paper: CXCR1: A Cancer Stem Cell Marker and Therapeutic Target in Solid Tumors, in the Journal: Biomedicines 2023, x of /2023/
- what: These effector states may be transition_states, similar to what the research shows for EMT states.
- how: Their results indicated that combining the CXCL8 ligand with the CXCR1 antibody decreased tumorsphere growth compared to CXCL8 treated and untreated samples.
- future: To streamline future experimentations therapeutics . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.